Blood-stable, cholesterol-free liposomes
US5043164A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jan 17, 1989 |
| Grant date | Aug 27, 1991 |
| Priority date | — |
| Expiry date | Jan 17, 2009 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10T428/2984
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Small unilamellar liposomes (d<600 nm) comprising an unsaturated phosphatidylethanolamine (PE) such as dioleoyl PE (DOPE) and a fatty acid such as oleic acid (OA) are stabilized by adding to a freshly prepared liposome suspension, an amphipile which has a high tendency to form micelles. Examples are shown for the following micelle-forming amphiphiles: lysophospholipide, gangliosides (GM.sub.1 and GTlb), sulfatide, synthetic glycopholipids such as sialo-lactosyl phosphatidylethanolamine, liopohilic drugs such as cytosine arabinoside diphosphate diacyglycerol, and proteins such as cytochrome b.sub.5, human high density lipoprotein (HDL), and human glycophorin A. The stabilized liposomes are resistant to the lytic action of albumin, the major blood component which causes the lysis of this type of liposome. Prior to the present invention, liposomes comprising PE and OA were typically stabilized by the incorporation of cholesterol.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.